Literature DB >> 26165403

Paraneoplastic Syndrome of Angiomatoid Fibrous Histiocytoma May Be Caused by EWSR1-CREB1 Fusion-induced Excessive Interleukin-6 Production.

Masaharu Akiyama1, Masayoshi Yamaoka, Yoko Mikami-Terao, Kentaro Yokoi, Takashi Inoue, Tomomasa Hiramatsu, Shuichi Ashizuka, Jyoji Yoshizawa, Hiroaki Katagi, Masahiro Ikegami, Hiroyuki Ida, Atsuko Nakazawa, Hajime Okita, Kenji Matsumoto.   

Abstract

We describe a 7-year-old girl with angiomatoid fibrous histiocytoma (AFH) presenting severe inflammatory symptoms. The cytokine/chemokine profile of serum samples before and after surgery demonstrated that interleukin (IL)-6 had decreased by the greatest percentage. The AFH cells were immunopathologically positive for IL-6 and Tyr705-phosphorylation of signal transducer and activator of transcription 3. The EWSR1-CREB1 fusion gene detected in the tumor leads to continuous activation of CREB1 and IL-6 production, because the promoter region of IL-6 has a CREB binding site. Thus, IL-6 plays pivotal roles in both paraneoplastic syndrome and the oncogenesis of AFH.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26165403     DOI: 10.1097/MPH.0000000000000390

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  5 in total

1.  Cranial angiomatoid fibrous histiocytoma: A case report and review of literature.

Authors:  Amanda E Sion; Rizwan A Tahir; Abir Mukherjee; Jack P Rock
Journal:  Surg Neurol Int       Date:  2020-09-18

2.  Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma.

Authors:  Hideaki Sabe; Akitomo Inoue; Shigenori Nagata; Yoshinori Imura; Toru Wakamatsu; Satoshi Takenaka; Hironari Tamiya
Journal:  Case Rep Oncol Med       Date:  2021-06-16

3.  Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma.

Authors:  Lauriane Eberst; Philippe A Cassier; Mehdi Brahmi; Franck Tirode; Jean-Yves Blay
Journal:  ESMO Open       Date:  2020-06

Review 4.  The spectrum of rare central nervous system (CNS) tumors with EWSR1-non-ETS fusions: experience from three pediatric institutions with review of the literature.

Authors:  Oscar Lopez-Nunez; Barbara Cafferata; Mariarita Santi; Sarangarajan Ranganathan; Thomas M Pearce; Scott M Kulich; Kelly M Bailey; Alberto Broniscer; Sabrina Rossi; Angelica Zin; MacLean P Nasrallah; Marilyn M Li; Yiming Zhong; Evelina Miele; Rita Alaggio; Lea F Surrey
Journal:  Brain Pathol       Date:  2020-11-06       Impact factor: 6.508

5.  An integrative histopathological and epigenetic characterization of primary intracranial mesenchymal tumors, FET:CREB-fused broadening the spectrum of tumor entities in comparison with their soft tissue counterparts.

Authors:  Arnault Tauziède-Espariat; Philipp Sievers; Frédérique Larousserie; Joseph Benzakoun; Delphine Guillemot; Gaëlle Pierron; Mathilde Duchesne; Emmanuelle Uro-Coste; Alexandre Roux; Alexandre Vasiljevic; Tanguy Fenouil; David Meyronet; Karima Mokhtari; Marc Polivka; Audrey Rousseau; Frédérique Bost-Bezeaud; Samir Akoury; Johan Pallud; Chiara Benevello; Lauren Hasty; Albane Gareton; Emmanuèle Lechapt; Fabrice Chrétien; Thomas Blauwblomme; Kévin Beccaria; Stéphanie Puget; Felix Sahm; Pascale Varlet
Journal:  Brain Pathol       Date:  2021-07-27       Impact factor: 6.508

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.